MedTrace Logo

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

NCT02239224 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies

Conditions

  • Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions

BIOLOGICAL

Placebo

Concentrate for solution for infusion

BIOLOGICAL

ATYR1940

Concentrate for solution for infusion

Sponsors & Collaborators

  • aTyr Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Sanjay Shukla, MD · aTyr Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-04
Primary Completion
2015-12-14
Completion
2015-12-14

Countries

  • United States
  • France
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239224 on ClinicalTrials.gov